2022 BO42451 – A Randomized Double-Blind Phase IIa Study Evaluating The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Crovalimab As Adjunct Treatment In Prevention Of Vaso-Occlusive Episodes (Voe) In Sickle Cell Disease (SCD)

Previous Post2022 BO42452 – A Phase Ib, Randomized, Placebo-Controlled Study Evaluating The Safety, Pharmacokinetics, Pharmacodynamics, And Efficacy Of Crovalimab For The Management Of Acute Uncomplicated Vaso Occlusive Episodes (VOE) In Patients With Sickle Cell Disease (SCD)